Stay updated with breaking news from Cramer Charitable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain.
CNBC's Jim Cramer has drawn investors' attention to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotechnology company currently in the late stages of developing a non-opioid drug to treat acute pain. The company's potential candidate, known as VX-548, is being positioned to address the critical issue of opioid addiction. Vertex Pharmaceuticals primarily generates its revenue from Trikafta, a cystic fibrosis treatment. However, their strategic shift towards addressing the pain management market has
Latest Reactions on Apple from Investors and Analysts Market Movers rounded up the latest reactions on Apple from investors and analysts. The pros,
However, CNBC's Jim Cramer acknowledged Thursday that "there is some movement between Ford and the UAW."
Chipotle edged higher during Wednesday trading after Oppenheimer shared a positive outlook for the chain.